Dr. Reckamp Describes the Use of Heat Shock Proteins

Karen Reckamp, MD
Published: Friday, Aug 19, 2011

Karen Reckamp, MD, MS, assistant professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, California, describes early studies in lung cancer that examine heat shock proteins as single agents, specifically in ALK translocated patients and some EGFR wild type adenocarcinoma patients, which are less well defined. The proteins have shown success when used as a single agent when there is a resistance to crizotinib. Studies are currently underway that are investigating heat shock proteins in chemotherapy combination therapies.
Karen Reckamp, MD, MS, assistant professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, California, describes early studies in lung cancer that examine heat shock proteins as single agents, specifically in ALK translocated patients and some EGFR wild type adenocarcinoma patients, which are less well defined. The proteins have shown success when used as a single agent when there is a resistance to crizotinib. Studies are currently underway that are investigating heat shock proteins in chemotherapy combination therapies.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x